JP2008537752A5 - - Google Patents

Download PDF

Info

Publication number
JP2008537752A5
JP2008537752A5 JP2008506633A JP2008506633A JP2008537752A5 JP 2008537752 A5 JP2008537752 A5 JP 2008537752A5 JP 2008506633 A JP2008506633 A JP 2008506633A JP 2008506633 A JP2008506633 A JP 2008506633A JP 2008537752 A5 JP2008537752 A5 JP 2008537752A5
Authority
JP
Japan
Prior art keywords
seq
sirna
antisense strand
strand consisting
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008506633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008537752A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/013645 external-priority patent/WO2006110813A2/en
Publication of JP2008537752A publication Critical patent/JP2008537752A/ja
Publication of JP2008537752A5 publication Critical patent/JP2008537752A5/ja
Pending legal-status Critical Current

Links

Images

JP2008506633A 2005-04-12 2006-04-12 がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法 Pending JP2008537752A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67071705P 2005-04-12 2005-04-12
PCT/US2006/013645 WO2006110813A2 (en) 2005-04-12 2006-04-12 Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases

Publications (2)

Publication Number Publication Date
JP2008537752A JP2008537752A (ja) 2008-09-25
JP2008537752A5 true JP2008537752A5 (https=) 2010-06-17

Family

ID=37087668

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008506633A Pending JP2008537752A (ja) 2005-04-12 2006-04-12 がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法

Country Status (12)

Country Link
US (5) US7893243B2 (https=)
EP (1) EP1877065A4 (https=)
JP (1) JP2008537752A (https=)
KR (1) KR20080041145A (https=)
CN (1) CN101277704A (https=)
AU (1) AU2006235489A1 (https=)
BR (1) BRPI0610499A2 (https=)
CA (1) CA2604441A1 (https=)
IL (1) IL186578A0 (https=)
MX (1) MX2007012766A (https=)
SG (1) SG161267A1 (https=)
WO (1) WO2006110813A2 (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2482904A1 (en) 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7592442B2 (en) 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US7691998B2 (en) 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US7619081B2 (en) 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US7977471B2 (en) 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
EP1711172A4 (en) 2003-12-23 2008-07-16 Univ Pennsylvania COMPOSITIONS AND METHODS FOR COMBINATION THERAPY OF ILLNESSES
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US7605250B2 (en) 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
JP2008537752A (ja) * 2005-04-12 2008-09-25 イントラディグム コーポレイション がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法
US20070082845A1 (en) * 2005-07-15 2007-04-12 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
KR20080061397A (ko) * 2005-10-14 2008-07-02 나스텍 파마수티컬 컴퍼니 인코포레이티드 Ｒｎａ 치료제용 펩티드 리보핵산 축합물 입자들의화합물들과 방법들
WO2007080902A1 (ja) * 2006-01-11 2007-07-19 Kyowa Hakko Kogyo Co., Ltd. 眼球において標的遺伝子の発現を抑制する組成物および眼球における疾患の治療剤
EP3342415B1 (en) 2006-08-08 2022-01-26 Rheinische Friedrich-Wilhelms-Universität Bonn Structure and use of 5' phosphate oligonucleotides
WO2008045576A2 (en) * 2006-10-12 2008-04-17 Yijia Liu Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
US20080274121A1 (en) * 2007-04-30 2008-11-06 Yao James C Inhibition of Angiogenesis by Mithramycin
CN101363027B (zh) * 2007-08-06 2011-07-27 武汉大学 携带短发夹rna的重组质粒的制备方法及用途
JP5273740B2 (ja) * 2007-09-07 2013-08-28 国立大学法人徳島大学 ｐ５３の発現促進方法およびそれに用いるｐ５３発現促進剤
WO2009051659A2 (en) * 2007-10-12 2009-04-23 Intradigm Corporation Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo
DK2217062T3 (en) 2007-11-06 2015-08-24 Sirnaomics Inc MULTI-TARGET READY RNAi therapeutics TO ARFRI WOUND HEALING OF SKIN
CN103351597A (zh) * 2007-11-07 2013-10-16 犹他大学研究基金会 可还原聚（酰胺乙烯亚胺）的可切割修饰以增强核苷酸递送
US20110312877A1 (en) * 2008-02-26 2011-12-22 Aparna Biosceiences Engineered tunable nanoparticles for delivery of therapeutics, diagnostics, and experimental compounds and related compositions for therapeutic use
ES2338400B1 (es) 2008-05-06 2011-09-14 David Benet Ferrus Conjunto de moleculas antiangiogenicas y su uso.
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
WO2009151539A1 (en) * 2008-05-24 2009-12-17 Sirnaomics, Inc. COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS
JP5832293B2 (ja) 2008-12-04 2015-12-16 オプコ ファーマシューティカルズ、エルエルシー 血管新生促進ｖｅｇｆイソ型を選択的に抑制する組成物および方法
WO2010078517A2 (en) * 2008-12-31 2010-07-08 Sirnaomics, Inc. Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer
DE102009006606A1 (de) * 2009-01-29 2010-08-05 Philipps-Universität Marburg Nicht-virales Transfektionsmittel
US20120114710A1 (en) * 2009-05-18 2012-05-10 Lynn Kirkpatrick Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
WO2011011061A2 (en) * 2009-07-21 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy
WO2011039646A2 (en) 2009-09-30 2011-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Papilloma virus -like particles for targeted gene delivery
JP2013523651A (ja) * 2010-03-24 2013-06-17 ノースイースタン ユニヴァーシティ 多重コンパートメントのマクロファージ送達
US8349308B2 (en) 2010-03-26 2013-01-08 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
WO2011140285A2 (en) 2010-05-04 2011-11-10 Sirnaomics, Inc. Combinations of tgfbeta and cox-2 inhibitors and methods for their therapeutic application
WO2012016139A2 (en) 2010-07-29 2012-02-02 Sirnaomics, Inc. Sirna compositions and methods for treatment of hpv and other infections
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
CN102727513B (zh) * 2011-04-15 2014-07-09 百奥迈科生物技术有限公司 靶向于组织因子基因的小核酸及其用途
US8592572B2 (en) * 2011-05-23 2013-11-26 Delta-Fly Pharma, Inc. Liposome containing shRNA molecule targeting a thymidylate synthase and use thereof
US20120301537A1 (en) * 2011-05-23 2012-11-29 Delta-Fly Pharma, Inc. LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF
WO2013114339A1 (en) 2012-02-02 2013-08-08 The Universityof British Columbia Combination therapy for cancer using hsp27 inhibitor and egfr tyrosine kinase inhibitors or anti-folates
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
US9801953B2 (en) 2012-10-15 2017-10-31 Emory University Nanoparticles carrying nucleic acid cassettes for expressing RNA
US9228189B2 (en) 2012-10-26 2016-01-05 Geron Corporation C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
WO2015021092A1 (en) * 2013-08-07 2015-02-12 Arrowhead Research Corporation Polyconjugates for delivery of rnai triggers to tumor cells in vivo
CN104635967B (zh) * 2013-11-12 2018-04-10 宸鸿光电科技股份有限公司 有机发光二极管触控显示设备
US20170143848A1 (en) * 2014-03-24 2017-05-25 Shire Human Genetic Therapies, Inc. Mrna therapy for the treatment of ocular diseases
EP3265107B1 (en) 2015-03-02 2024-10-02 180 Therapeutics LP Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
GB201904337D0 (en) * 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
CN111298129B (zh) * 2019-08-28 2023-05-09 中国人民解放军陆军军医大学第二附属医院 二甲双胍介导核酸纳米材料自组装方法及采用该方法制备的纳米制剂和应用
KR20240004316A (ko) 2021-04-27 2024-01-11 4디 몰레큘러 테라퓨틱스 아이엔씨. 혈관신생과 관련된 안구 질환의 치료를 위한 조성물 및 방법
WO2025247332A1 (zh) * 2024-05-31 2025-12-04 石药集团中奇制药技术（石家庄）有限公司 一种抑制vegfa基因和ang-2基因表达的双靶核酸分子

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5726152A (en) * 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
DE69229454T2 (de) * 1991-03-28 2000-01-05 Merck & Co., Inc. Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US6743909B2 (en) * 2002-06-17 2004-06-01 Isis Pharmaceuticals, Inc. Antisense modulation of PTPN12 expression
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US6150092A (en) * 1994-06-27 2000-11-21 Taogosei Company, Ltd. Antisense nucleic acid compound targeted to VEGF
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
NZ328371A (en) 1994-12-23 1999-05-28 Ludwig Inst Cancer Res Method of detecting a ligand capable of binding the receptor protein neuroepithelial tyrosine kinase (nyk) and its use in therapeutic compositions
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
EP0845992B1 (en) * 1995-08-15 2002-11-20 Connetics Corporation Use of relaxin for promoting angiogenesis
US7005505B1 (en) * 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US20040142895A1 (en) * 1995-10-26 2004-07-22 Sirna Therapeutics, Inc. Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
EP1426444A3 (en) 1996-09-06 2004-06-16 Technion Research & Development Co., Ltd. Use of the angiogenic factor VEGF145 in treating cardiovascular diseases
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
US6395707B1 (en) * 1997-02-14 2002-05-28 Genentech, Inc. Methods of treatment utilizing variants of vascular endothelial cell growth factor
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
US6479729B1 (en) * 1998-02-06 2002-11-12 The Johns Hopkins University Mouse model for ocular neovascularization
JP2002502608A (ja) * 1998-02-06 2002-01-29 コラテラル・セラピューティックス・インコーポレイテッド 血管新生促進因子である血管内皮細胞成長因子：ｖｅｇｆの変異体
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
DE69919869T2 (de) * 1998-06-10 2005-09-29 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Stimulierung des immunsystems
CA2329160A1 (en) 1998-06-11 1999-12-16 University Of Medicine & Dentistry Of New Jersey Wound treatment through inhibition of adenosine diphosphate ribosyl transferase
EP0979869A1 (en) * 1998-08-07 2000-02-16 Hoechst Marion Roussel Deutschland GmbH Short oligonucleotides for the inhibition of VEGF expression
ES2216630T3 (es) * 1998-09-09 2004-10-16 Scios Inc Metodos de tratar la hipertension dependiente de la sal.
US6677300B1 (en) * 1998-09-09 2004-01-13 Scios, Inc. Treatment of microvascular angiopathies
EP1417971A3 (en) 1998-09-09 2004-06-30 Scios Inc. Use of an angiogenic factor for the treatment of microvascular angiopathies
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
US6916915B1 (en) * 1998-11-20 2005-07-12 Duke University Stressor regulated genes
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
IL128852A0 (en) * 1999-03-05 2000-01-31 Compugen Ltd Novel nucleic acid and amino acid sequences
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
DE19910419A1 (de) 1999-03-10 2000-09-21 Aventis Pharma Gmbh Zielzellspezifische, multivalente Proteine (MVP)
US6943153B1 (en) * 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6475796B1 (en) * 1999-05-20 2002-11-05 Scios, Inc. Vascular endothelial growth factor variants
US6187822B1 (en) * 1999-06-11 2001-02-13 University Of Medicine & Dentistry Of Nj Wound treatment through inhibition of adenosine diphosphate ribosyl transferase
WO2001027292A2 (en) 1999-10-08 2001-04-19 Biofocus Discovery Limited Methods and compositions for targeting a cell
US6770633B1 (en) * 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
US7078382B1 (en) * 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
CN1307303C (zh) * 2000-01-19 2007-03-28 帕卡什·S·吉尔 针对反义vegf寡核苷酸的方法和组合物
WO2001058468A1 (en) 2000-02-09 2001-08-16 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
WO2005019453A2 (en) * 2001-05-18 2005-03-03 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
AU3988401A (en) * 2000-02-25 2001-09-03 Ludwig Inst Cancer Res Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US6727066B2 (en) * 2000-07-28 2004-04-27 Incyte Corporation Genes expressed in treated human C3A liver cell cultures
US6673549B1 (en) * 2000-10-12 2004-01-06 Incyte Corporation Genes expressed in C3A liver cell cultures treated with steroids
US20030186920A1 (en) 2000-10-13 2003-10-02 Sirois Martin G. Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof
AU2002305236A1 (en) 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent
US20070021360A1 (en) 2001-04-24 2007-01-25 Nyce Jonathan W Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050222066A1 (en) * 2001-05-18 2005-10-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003070910A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2004111237A1 (en) 2003-04-16 2004-12-23 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET-DERIVED ENDOTHELIAL CELL GROWTH FACTOR (ECGF1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1262199A1 (en) 2001-05-23 2002-12-04 Fornix Biosciences N.V. Vectors for enhanced expression of VEGF for disease treatment
CA2448320A1 (en) 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Ribozyme based treatment of female reproductive diseases
US7101977B2 (en) * 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
JP2003088388A (ja) * 2001-09-14 2003-03-25 Herikkusu Kenkyusho:Kk 新規な全長ｃＤＮＡ
EP1293569A3 (en) 2001-09-14 2004-03-31 Research Association for Biotechnology Full-length cDNAs
JP2005508396A (ja) * 2001-11-02 2005-03-31 イントラディグム、コーポレイション 核酸送達ビヒクルのための治療方法
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
US20050075304A1 (en) * 2001-11-30 2005-04-07 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US6927779B2 (en) * 2002-05-13 2005-08-09 Large Scale Biology Corporation Web-based well plate information retrieval and display system
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
MXPA05003287A (es) * 2002-09-28 2005-07-05 Massachusetts Inst Technology Influenza terapeutica.
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
FR2835838B1 (fr) 2003-02-06 2007-11-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene codant pour un facteur de transcription
FR2835837B1 (fr) 2003-02-06 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leurs utilisation pour reprimer specifiquement un gene codant pour un facteur de croissance
AU2004227414A1 (en) 2003-04-03 2004-10-21 Alnylam Pharmaceuticals iRNA conjugates
US20050096370A1 (en) 2003-04-07 2005-05-05 Bizbiotech Co., Ltd. Method for inhibiting tumor angiogenesis and tumor growth
DE10316701A1 (de) 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
US20050019927A1 (en) * 2003-07-13 2005-01-27 Markus Hildinger DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER
EP1548445A3 (en) 2003-12-22 2005-11-23 F. Hoffmann-La Roche Ag Novel targets for obesity from fat tissue
EP1713819A4 (en) * 2004-02-05 2007-11-14 Intradigm Corp METHOD AND COMPOSITIONS FOR COMBINING RNAI THERAPEUTICS
EP1711510A4 (en) * 2004-02-05 2008-11-26 Intradigm Corp RNAI THERAPEUTIC FOR THE TREATMENT OF EYE DISEASES WITH VASCULAR REPRODUCTION
AU2005222902B2 (en) 2004-03-12 2010-06-10 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
EP1752536A4 (en) 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
EP1607485A1 (en) 2004-06-14 2005-12-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for quantifying VEGF121 isoform in a biological sample
AU2005310131A1 (en) 2004-11-17 2006-06-08 University Of Maryland, Baltimore Highly branched HK peptides as effective carriers of siRNA
JP2008537752A (ja) * 2005-04-12 2008-09-25 イントラディグム コーポレイション がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
EP1714970A1 (en) 2005-04-22 2006-10-25 Universität des Saarlandes Use of inhibitors of RNAse A-family enzymes for stabilizing oligonucleotides having RNA interfering activity
CN100374573C (zh) 2006-04-14 2008-03-12 中国医学科学院医药生物技术研究所 一种可稳定表达VEGF shRNA的载体pCD-VEGF
WO2008045576A2 (en) 2006-10-12 2008-04-17 Yijia Liu Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
WO2009051659A2 (en) 2007-10-12 2009-04-23 Intradigm Corporation Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo

Similar Documents

Publication Publication Date Title
JP2008537752A5 (https=)
JP2008537752A (ja) がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法
US7893244B2 (en) Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
Wei et al. Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles
Lee et al. Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo
Guo et al. ICAM-1-targeted, Lcn2 siRNA-encapsulating liposomes are potent anti-angiogenic agents for triple negative breast cancer
Woodrow et al. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA
Wang et al. Targeted delivery of tumor suppressor microRNA-1 by transferrin-conjugated lipopolyplex nanoparticles to patient-derived glioblastoma stem cells
Dong et al. Therapeutic potential of targeted multifunctional nanocomplex co-delivery of siRNA and low-dose doxorubicin in breast cancer
US20090247604A1 (en) RNAi Therapeutics for Treatment of Eye Neovascularization Diseases
Lee et al. Brain‐targeted exosome‐mimetic cell membrane nanovesicles with therapeutic oligonucleotides elicit anti‐tumor effects in glioblastoma animal models
WO2016145005A1 (en) Rna nanoparticles for brain tumor treatment
JP2007528899A (ja) 受容体特異的ナノ容器を使用するショートヘアピンｒｎａをコードする遺伝子の送達
WO2008045576A2 (en) Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
Wang et al. Rational design of multimodal therapeutic nanosystems for effective inhibition of tumor growth and metastasis
JP2010509401A (ja) アンチセンスオリゴヌクレオチドの効率的な核への送達
Gujrati et al. Targeted systemic delivery of therapeutic siRNA
Shim et al. Small interfering RNAs (siRNAs) as cancer therapeutics
Yin et al. Asymmetric siRNA targeting the bcl-2 gene inhibits the proliferation of cancer cells in vitro and in vivo
Guo et al. RNA nanoparticles for brain tumor treatment
Momin et al. The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint. Cells 2021, 10, 3097
HK1127276A (en) Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
Kalogeros Tandem peptides targeting HER2 for delivery of CD44 siRNA into HER2+ breast cancer cells in vitro
Rodriguez‐Aguayo et al. RNAi in cancer therapy
Alshaer Functionalizing liposomes with aptamers for active targeting of tumor cells